Press release
Agitation in Alzheimer's Disease Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working, DelveInsight | Eli Lilly and Co, BioVie Inc, AB Science SA, Annovis Bio Inc, Cognition Therapeutics Inc, Coya Therapeutics Inc, Actinogen Medi
Agitation in Alzheimer's Disease Market, DelveInsight
DelveInsight has launched a new report on "Agitation in Alzheimer's Disease - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Agitation in Alzheimer's Disease, historical and forecasted epidemiology as well as the Agitation in Alzheimer's Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Download our sample pages @ https://www.delveinsight.com/report-store/agitation-in-alzheimer-disease?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Recent advancements in the Agitation in Alzheimer's Disease Market:
In March 2025, BioXcel Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) had completed the inspection of a single site involved in its TRANQUILITY II Phase 3 trial under 21 C.F.R. 20.64(d)(3) and issued the Establishment Inspection Report.
Some of the key facts of the Agitation in Alzheimer's Disease Market Report:
In Europe, the prevalence of agitation in Alzheimer's patients has been reported to range from 24% to 88%. Additionally, 14 studies (47%) indicated an agitation prevalence rate of 50% or higher.
The Agitation in Alzheimer's Disease market is expected to grow steadily at a consistent CAGR from 2024 to 2034, driven by several factors. A key contributor to this growth is the increasing aging population, particularly in developed nations where Alzheimer's disease is more prevalent. As life expectancy rises, the number of individuals affected by Alzheimer's and associated symptoms, such as agitation, is also projected to increase.
Epidemiological studies show that agitation is a common symptom among Alzheimer's patients, though its exact prevalence varies due to differences in diagnostic criteria and study methods. Estimates suggest that up to 50% of individuals with Alzheimer's experience agitation at some stage of their illness.
Managing agitation in Alzheimer's disease remains a significant challenge due to the absence of early detection methods, targeted treatments, and curative therapies. Currently, REXULTI (brexpiprazole) is the first and only FDA-approved medication specifically for agitation associated with dementia due to Alzheimer's disease.
Several pharmaceutical companies are actively developing treatments for this condition. Leading industry players, including Johnson & Johnson, Otsuka, IGC Pharma, and Bioxcel, are working on innovative therapies to meet the unmet needs of Alzheimer's patients experiencing agitation. Emerging drug candidates such as AXS-05 (Axsome Therapeutics), AVP-786 (Otsuka Pharmaceutical), and IGC-AD1 (IGC Pharma) are expected to enter the market during the forecast period, potentially shaping market dynamics and expanding treatment options.
Key benefits of the Agitation in Alzheimer's Disease market report:
Agitation in Alzheimer's Disease market report covers a descriptive overview and comprehensive insight of the Agitation in Alzheimer's Disease Epidemiology and Agitation in Alzheimer's Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Agitation in Alzheimer's Disease market report provides insights on the current and emerging therapies.
Agitation in Alzheimer's Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Agitation in Alzheimer's Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Agitation in Alzheimer's Disease market.
Got queries? Click here to know more about the Agitation in Alzheimer's Disease Market Landscape https://www.delveinsight.com/sample-request/agitation-in-alzheimer-disease?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Agitation in Alzheimer's Disease Overview
As Alzheimer's disease progresses, individuals may exhibit agitation or aggression. Agitation refers to feelings of restlessness or anxiety, making it difficult for the person to remain calm. This may manifest as pacing, difficulty sleeping, or aggressive behaviors, such as verbal outbursts or attempts to harm others. As a result, agitation is a common and distressing symptom in Alzheimer's disease, often leading to disruptive behaviors.
The treatment of agitation in Alzheimer's is complex, as it arises from a combination of biological, psychological, and environmental factors. Neurobiological changes, such as neurotransmitter imbalances and brain structural damage, contribute to behavioral disturbances. Additionally, underlying conditions like pain, infections, sleep disturbances, confusion, and medication side effects can worsen agitation. Fear and perceived threats may also trigger these behaviors.
Both individuals with Alzheimer's and their caregivers may require support to manage agitation and aggression. While non-pharmacological approaches can be beneficial, certain medications and therapeutic interventions can help alleviate symptoms and improve quality of life.
Agitation in Alzheimer's Disease Market Outlook
The primary therapeutic goal in managing agitation associated with Alzheimer's disease is to control symptoms and enhance patient well-being. Current treatment approaches often include antipsychotic medications such as risperidone and quetiapine, though these drugs come with risks, including sedation, metabolic side effects, and an increased likelihood of strokes in elderly patients. In addition to pharmacological treatments, non-drug interventions like music therapy, aromatherapy, and structured routines play a crucial role in managing aggression and providing alternatives to medication.
Most pharmacological treatments for Alzheimer's-related agitation target dopamine and serotonin receptors, helping to alleviate behavioral symptoms. As a result, both drug-based and non-drug approaches should be incorporated into a comprehensive treatment plan for patients with agitation in Alzheimer's disease.
Commonly used medications for managing agitation include risperidone, quetiapine, aripiprazole, carbamazepine, citalopram, gabapentin, prazosin, trazodone, lorazepam, and cyproterone acetate. However, while these medications can be effective, they also carry risks such as falls, excessive sedation, and metabolic disturbances.
REXULTI (brexpiprazole) is the first and only FDA-approved drug for treating agitation related to Alzheimer's disease dementia. It works through a combination of mechanisms, acting as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors while also serving as an antagonist at serotonin 5-HT2A receptors, helping to regulate mood and behavior.
Discover how the Alzheimer's disease market is rising @ https://www.delveinsight.com/report-store/agitation-in-alzheimer-disease?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Agitation in Alzheimer's Disease Marketed Drugs
REXULTI (brexpiprazole): Otsuka Pharmaceuticals
Agitation in Alzheimer's Disease Emerging Drugs
AXS-05: Axsome Therapeutics
AVP-786: Otsuka Pharmaceutical Development & Commercialization
BXCL501: BioXcel Therapeutics
Scope of the Agitation in Alzheimer's Disease Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Agitation in Alzheimer's Disease Companies: Eli Lilly and Co, BioVie Inc, AB Science SA, Annovis Bio Inc, Cognition Therapeutics Inc, Coya Therapeutics Inc, Actinogen Medical Limited, AC Immune SA, Biogen Inc, Longeveron Inc, and others
Agitation in Alzheimer's Disease Therapeutic Assessment: Agitation in Alzheimer's Disease current marketed and Agitation in Alzheimer's Disease emerging therapies
Agitation in Alzheimer's Disease Market Dynamics: Agitation in Alzheimer's Disease market drivers and Agitation in Alzheimer's Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Agitation in Alzheimer's Disease Unmet Needs, KOL's views, Analyst's views, Agitation in Alzheimer's Disease Market Access and Reimbursement
Request for sample pages @ https://www.delveinsight.com/sample-request/agitation-in-alzheimer-disease?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Agitation in Alzheimer's Disease Patient Share (%) Overview at a Glance
5. Agitation in Alzheimer's Disease Market Overview at a Glance
6. Agitation in Alzheimer's Disease Disease Background and Overview
7. Agitation in Alzheimer's Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Agitation in Alzheimer's Disease
9. Agitation in Alzheimer's Disease Current Treatment and Medical Practices
10. Unmet Needs
11. Agitation in Alzheimer's Disease Emerging Therapies
12. Agitation in Alzheimer's Disease Market Outlook
13. Country-Wise Agitation in Alzheimer's Disease Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Agitation in Alzheimer's Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Agitation in Alzheimer's Disease Market Outlook 2034 https://www.delveinsight.com/report-store/agitation-in-alzheimer-disease?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Related Reports:
Agitation in Alzheimer's Disease Pipeline Insights, DelveInsight
"Agitation in Alzheimer's Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Agitation in Alzheimer's Disease market. A detailed picture of the Agitation in Alzheimer's Disease pipeline landscape is provided, which includes the disease overview and Agitation in Alzheimer's Disease treatment guidelines.
Contact Info:
Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Agitation in Alzheimer's Disease Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working, DelveInsight | Eli Lilly and Co, BioVie Inc, AB Science SA, Annovis Bio Inc, Cognition Therapeutics Inc, Coya Therapeutics Inc, Actinogen Medi here
News-ID: 3937006 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Alzheimer
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…
